AbbVie FY2026 Earnings Forecast Lowered by Erste Group Bank

AbbVie Inc. (NYSE:ABBV) – Research analysts at Erste Group Bank reduced their FY2026 earnings per share estimates for AbbVie in a report released on Wednesday, October 21st. Erste Group Bank analyst H. Engel now anticipates that the company will earn $13.90 per share for the year, down from their previous forecast of $14.00. Erste Group Bank has a “Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $13.94 per share.

ABBV has been the subject of several other reports. BMO Capital Markets increased their price objective on shares of AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Scotiabank boosted their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Royal Bank Of Canada restated an “outperform” rating and issued a $280.00 target price on shares of AbbVie in a research report on Tuesday, October 13th. Cantor Fitzgerald increased their price target on AbbVie from $285.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group reiterated a “neutral” rating on shares of AbbVie in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.07.

AbbVie Price Performance

Shares of AbbVie stock opened at $284.59 on Friday. The business’s fifty day moving average price is $265.60 and its two-hundred day moving average price is $241.46. The company has a market capitalization of $502.80 billion, a P/E ratio of 80.39, a PEG ratio of 1.30 and a beta of 0.24. AbbVie has a 1-year low of $190.75 and a 1-year high of $291.40.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the company earned $2.97 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is owned by company insiders.

Institutional Investors Weigh In On AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp raised its holdings in AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of AbbVie during the 2nd quarter worth approximately $2,905,952,000. Finally, Deutsche Bank AG increased its position in shares of AbbVie by 13.0% during the second quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported that its investigational lutikizumab met the primary endpoint and eight ranked secondary endpoints in the Phase 3 INTREPID trial for moderate-to-severe hidradenitis suppurativa. The drug improved disease symptoms, reduced flares and was generally well tolerated, supporting the company’s effort to expand its immunology pipeline. AbbVie Announces INTREPID Trial Results
• Positive Sentiment: Investors continue to point to strong growth from Skyrizi and Rinvoq, progress in oncology and potential successors to key immunology products. Recent Crohn’s disease data and an eczema candidate could help AbbVie manage future patent expirations and support longer-term revenue growth. Great News for AbbVie Stock Investors
• Neutral Sentiment: Wall Street brokers broadly rate ABBV as a Buy, while income investors value its long record of annual dividend increases. However, higher interest rates can make high-yield alternatives more competitive and may limit valuation expansion. What Higher Interest Rates Mean for Dividend Stocks
• Negative Sentiment: Although lutikizumab technically met the INTREPID trial goals, analysts characterized the efficacy as below expectations, with the advantage over placebo viewed as underwhelming. That raises questions about the drug’s commercial potential and allowed rival MoonLake’s shares to benefit. Lutikizumab Phase 3 Results
• Negative Sentiment: AbbVie also halted an early-stage liver-cancer combination trial, adding a setback to its oncology pipeline. With the stock near its 52-week high and patent cliffs approaching, investors may demand strong earnings and clear replacement-product progress to justify the valuation. AbbVie Halts Liver Cancer Trial

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.